Most people leave the hospital after a blood clot with two things: a prescription and a vague instruction to follow up with somebody. Nobody explains what happens at month three.
That gap is why patients across Baltimore County call our office in White Marsh. They are not confused about the pill. They are confused about the exit.
Blood clots are common enough that the question comes up constantly. The CDC estimates that
as many as 900,000 Americans are affected by a venous blood clot each year, and that 60,000 to 100,000 die from one. More than a third of diagnosed cases trace back to a recent hospital stay, and most of those clots show up after the patient has already gone home.
So the question is fair, and it deserves a real answer instead of "we’ll see."
The treatment is not one block of time
Hematologists split anticoagulation into three phases, and the language matters because the decision points sit at the seams.
Initial management covers the first 5 to 21 days, when the clot is fresh and the dosing is usually higher. Primary treatment runs from there through roughly month three to month six. Secondary prevention is everything after that, and it exists for one reason: stopping the next clot rather than treating the one you already had.
When a patient asks how long they are on a blood thinner, they are almost always asking about that third phase. The first two are settled. The third is a judgment call, and it is a core part of the
anticoagulation management we provide for patients on DOACs and warfarin.
Provoked or unprovoked decides almost everything
Here is the single question that shapes the answer. Did something cause the clot?
A clot that follows a knee replacement, a long hospitalization, a leg cast, or a course of estrogen is called provoked. The trigger came, the clot came, and the trigger is gone. The
2020 American Society of Hematology guidelines for treating DVT and pulmonary embolism favor a shorter course, three to six months, when a clot is tied to a transient risk factor like that.
A clot that arrives with no explanation is called unprovoked. Nothing caused it, which means nothing was removed. For most unprovoked clots, and for clots tied to a risk factor that is not going away, the same ASH guidelines suggest indefinite anticoagulation rather than stopping at six months. For a patient who has already had a second unprovoked clot, that recommendation is strong rather than conditional.
That is the whole fork in the road. Same medication, same dose, radically different endpoint, decided by a history question.
A clean ultrasound does not close the case
Patients often arrive holding a repeat leg ultrasound or a normal D-dimer result, believing it settles the matter.
It usually does not.
The ASH panel specifically suggests against using prognostic scores, D-dimer testing, or repeat venous ultrasound as the routine way to decide how long anticoagulation continues. Those tests answer a different question than the one being asked. A resolved clot on imaging tells you the old clot is gone. It does not tell you what your body will do next year.
Recurrence is the real concern, and it is not rare. About one in three people who have had a venous clot will have another one within ten years.
The other half of the ledger is bleeding
Every month on a blood thinner buys protection against a clot and spends a little risk of bleeding. That trade is the actual calculation, and it is personal.
Age, kidney function, prior gastrointestinal bleeding, alcohol use, fall risk, and other medications all sit on the bleeding side. One detail catches people off guard: if you were taking daily aspirin for heart health and then started an anticoagulant, ASH suggests suspending the aspirin for the duration of anticoagulation in patients with stable cardiovascular disease, because stacking the two raises bleeding risk without a matching benefit.
That is not a decision to make by reading a label. It belongs in a conversation with someone who does this every week.
Where this decision should get made
The uncomfortable truth is that the anticoagulation duration decision often has no clear owner. The hospital treated the acute event. The primary care office inherited the refills. Nobody was assigned month six.
Brodsky Hematology in White Marsh serves Nottingham, Perry Hall, Towson, and the surrounding Baltimore area, and this is exactly the handoff we are built for. Dr. Max Brodsky is board-certified in Internal Medicine and completed his hematology fellowship at Johns Hopkins.
Our practice focuses on
benign hematology, meaning blood disorders that are not cancer. We also take rapid post-discharge referrals, so patients recently home from the hospital do not sit in limbo.
If you are on a blood thinner and nobody has told you when or whether it stops, that is the appointment to make.
Schedule a consultation with Brodsky Hematology or call the White Marsh office at 410.653.4002.
Bring the discharge paperwork. The details of how the clot happened are the details that decide the plan.
